SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community celebrates the FDA approval of BYSANTI for schizophrenia and bipolar I disorder, anticipating a significant stock re-rating and potential for a short squeeze. This approval also validates the company's pipeline, particularly Tradipitant for GLP-1 induced nausea, which many believe positions Vanda as a strong takeover candidate.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Crowdstrike is trending due to market reactions surrounding the release of Anthropic's Claude Code Security tool, which has prompted a re-evaluation of cybersecurity valuations with active community debate on its competitive impact and whether the stock is oversold.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is heavily discussed due to recent AI disruption fears within the cybersecurity sector, sparked by Anthropic's Claude Code Security tool. The community is sharply divided, with some panicking over AI's potential to replace existing solutions, while others argue that robust platforms like Zscaler have strong moats and will integrate AI, viewing the current sell-off as an opportunity ahead of upcoming earnings.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending following contradictory reports on U.S. Immigration and Customs Enforcement's (ICE) future strategy, with news of reduced private facility reliance sparking a sell-off, clashing with discussions around robust new contracts and significant ICE expansion plans. This divergence has investors deeply split, with many seeing a deep value buying opportunity while others remain cautious of ongoing political headwinds.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending due to its increasing utility in the AI space, notably joining NVIDIA's Inception Program, and expanding cross-chain capabilities through its NEAR Intents and Chain Signatures technologies. While recent price dips have fueled community discussions around accumulation, many believe its strong fundamentals and growing ecosystem position it as an undervalued asset for the upcoming altcoin season.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is actively trending amidst community confusion and frustration following a Supreme Court ruling on tariffs, which many expected to be favorable yet led to mixed stock performance. This comes as investors also weigh Nike's ongoing turnaround strategy, recent layoffs, and a federal DEI probe.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BridgeBio Pharma is trending following positive Phase 3 results for its oral achondroplasia treatment, infigratinib, which showed significant improvements and has generated excitement for its best-in-class potential. This latest success, coupled with other recent late-stage pipeline wins and robust Attruby sales, has the community buzzing about BridgeBio's undervalued status and strong acquisition prospects.

Fiverr International Ltd. develops an e-commerce platform that allows people to buy and sell digital services. It operates through the following geographical segments: U.S., Europe, Asia Pacific, Rest of the World and Israel. The firm offers digital marketing, graphics and design, video and animation, writing and translation, and music and audio. The company was founded by Micha Kaufman and Shai Wininger in 2009 and is headquartered in Tel Aviv, Israel.

Fiverr International Ltd

Fiverr is actively discussed following its latest earnings, which saw an EPS beat offset by cautious forward guidance, signaling an expensive and extended AI transformation. Sentiment is sharply divided, with bulls highlighting the company's profitability and strong cash position as a deep value opportunity, while bears focus on declining active buyers and the perceived threat of AI to its core gig economy model.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is actively discussed following the Supreme Court's decision against emergency tariffs, with many questioning the stock's lack of a significant rally, while simultaneously navigating controversy over a "sheer" new product line, founder criticism of board leadership and product quality, and anticipation of a new CEO.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is trending as the community actively discusses its potential for a significant future recovery, with many expressing hope it will "rise from the ashes." Despite its current low price, its "move-to-earn" utility and staking opportunities are key talking points among those accumulating the crypto.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jupiter Asset Management Ltd. Purchases 129,971 Shares of Halozyme Therapeutics, Inc. $HALO

Jupiter Asset Management Ltd. boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.4% in the 3rd quarter, according to its most recent filing with the...

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00

Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday...

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $75.00 at Wells Fargo & Company

Wells Fargo & Company increased their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an "equal weight" rating in a research report on Thursday...

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% Following Weak Earnings

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Down 8.7% on Disappointing Earnings...

Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues

HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.

Halozyme Therapeutics, Inc. $HALO Shares Sold by Hodges Capital Management Inc.

Hodges Capital Management Inc. trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 21.0% during the third quarter, according to its most recent filing with the...

Halozyme Therapeutics (NASDAQ:HALO) Announces Quarterly Earnings Results, Misses Expectations By $2.16 EPS

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing...

Halozyme Therapeutics Q4 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) executives highlighted what they described as a significant and value-creating 2025, pointing to accelerating royalty growth from ENHANZE-enabled products...

Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -111.16% and +0.70%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

HALO
Halozyme Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HALO News

HALOHalozyme Therapeutics Inc.